Author: Dizal (Jiangsu) Pharmaceutical Company Limited

Posted Date:

May 27, 2026

Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

Dizal (Jiangsu) Pharmaceutical Company Limited

May 27, 2026
Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

Dizal (Jiangsu) Pharmaceutical Company Limited

April 21, 2026
Dizal’s ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026

Dizal (Jiangsu) Pharmaceutical Company Limited

March 27, 2026
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

Dizal (Jiangsu) Pharmaceutical Company Limited

March 21, 2026